ERBB2 and lung adenocarcinoma: In particular, the small molecule EGFR TKI inhibitors, erlotinib and gefitinib show dramatic activity in EGFR-mutated lung adenocarcinomas and the anti-ErbB2 antibody, trastuzumab and the dual EGFR/ErbB2 inhibitor, lapatinib have proven benefits in ErbB2-amplified malignancies [3, 7–11].